TheraRadar
Clinical-Stage Companies / Catalyst

Catalyst

Pre-Approval PRO BETA

Also known as: Catalyst Pharmaceuticals, Inc., Catalyst Biosciences

⚫

Inactive Company

No clinical trial activity in 3+ years. This company may have been acquired, shut down, or pivoted away from clinical development. Last trial started: 5/17/2021

17
Total Trials
7
Phase 3
8
Phase 2
0
Recruiting
181
Score

Pipeline by Phase

Phase 3
7
Phase 2
8
Phase 1
4

Therapeutic Focus

Hemophilia A With Inhibitor Hemophilia B With Inhibitor Cocaine Dependence Hemophilia A Hemophilia B

Clinical Trials (17)

NCT03579966 Phase 3 TERMINATED

Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)

Started: 6/11/2018

NCT03304054 Phase 3 COMPLETED

Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG

Started: 4/18/2018

NCT02562066 Phase 3 COMPLETED

Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes

Started: 1/1/2016

NCT02970162 Phase 3 COMPLETED

Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS)

Started: 11/1/2016

NCT01377922 Phase 3 COMPLETED

A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)

Started: 6/1/2011

NCT04489537 Phase 3 TERMINATED

Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Hemophilia A or B

Started: 5/4/2021

NCT03819660 Phase 2 TERMINATED

Long Term Safety of Amifampridine Phosphate in Spinal Muscular Atrophy 3

Started: 3/7/2019

NCT03781479 Phase 2 COMPLETED

Controlled Trial to Evaluate Amifampridine Phosphate in Spinal Muscular Atrophy Type 3 Patients

Started: 1/21/2019

NCT00730522 Phase 2 TERMINATED

Safety and Efficacy Study of Vigabatrin to Treat Methamphetamine Dependence

Started: 7/1/2008

NCT01281202 Phase 2 COMPLETED

Vigabatrin for the Treatment of Cocaine Dependency

Started: 1/1/2011

NCT00611130 Phase 2 COMPLETED

Vigabatrin for Treatment of Cocaine Dependence

Started: 1/1/2008

NCT03407651 Phase 2 COMPLETED

Study of Coagulation Factor VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia A and B

Started: 12/18/2017

NCT03995784 Phase 2 COMPLETED

Study of Next-Generation Recombinant Factor IX Variant in Adult Subjects With Hemophilia B

Started: 6/18/2019

NCT01493596 Phase 1 COMPLETED

A Safety, Tolerability and Pharmacokinetic Study of CPP-115

Started: 12/1/2011

NCT04548791 Phase 1 TERMINATED

Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders

Started: 5/17/2021

NCT04072237 Phase 1 COMPLETED

Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia

Started: 9/24/2019

NCT01439971 Phase 1 COMPLETED

Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d) In Adult Subjects With Hemophilia

Started: 12/1/2011

Drug Candidates

Amifampridine Phosphate Amifampridine Phosphate 10 MG Oral Tablet CPP-115 amifampridine phosphate CPP-109 vigabatrin Vigabatrin vigabatrin Coagulation Factor VIIa variant MarzAA MarzAA (marzeptacog alfa [activated])
Activity Status: Inactive
Last Trial Started: 5/17/2021
Last Trial Ended: 8/5/2022
Trials (12 months): 0
Completed Trials: 12
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.